Literature DB >> 26022800

Clinical and prognostic role of ammonia in advanced decompensated heart failure. The cardio-abdominal syndrome?

Simone Frea1, Virginia Bovolo1, Stefano Pidello2, Federico G Canavosio1, Michela Botta1, Serena Bergerone1, Fiorenzo Gaita1.   

Abstract

BACKGROUND: Advanced heart failure is associated with end-organ damage. Recent literature suggested an intriguing crosstalk between failing heart, abdomen and kidneys. Venous ammonia, as a by-product of the gut, could be a marker of abdominal injury in heart failure patients. The aim of the study was to investigate the clinical and prognostic role of ammonia in patients with advanced decompensated heart failure (ADHF). METHODS &
RESULTS: 90 patients admitted with ADHF were prospectively studied. The prognostic role of ammonia at admission was evaluated. Primary end-points were: a composite of cardiac death, urgent heart transplantation and mechanical circulatory support at 3 months and need for renal replacement therapies (RRT). In the study cohort (age 59.0 ± 12.0 years, FE 21.6 ± 9.0%, INTERMACS profile 3.7 ± 0.9, creatinine 1.71 ± 0.95 mg/dl) 27 patients (30%) underwent the cardiac composite endpoint, while 9 patients (10%) needed RRT. At ROC curve analysis ammonia ≥ 130 μg/dl (abdominal damage) showed the best diagnostic accuracy. At multivariate analysis abdominal damage predicted the cardiac composite endpoint. Abdominal damage further increased risk among patient with cold profile at admission (HR 2.7, 95% CI 1.1-7.0, p = 0.046). At multivariate analysis abdominal damage also predicted need for RRT (OR 10.8, 95% CI 1.5-75.8, p = 0.017). The combined use of estimated right atrial pressure and ammonia showed the highest diagnostic accuracy and a very high specificity in prediction of need for RRT.
CONCLUSION: In a selected population admitted for ADHF ammonia, as a marker of abdominal derangement, predicted adverse cardiac events and need for RRT.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Advanced heart failure; Ammonia; Prognosis; Renal replacement therapies

Mesh:

Substances:

Year:  2015        PMID: 26022800     DOI: 10.1016/j.ijcard.2015.05.061

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  4 in total

1.  Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis.

Authors:  Avinash Kumar; Gangarao Davuluri; Rafaella Nascimento E Silva; Marielle P K J Engelen; Gabrie A M Ten Have; Richard Prayson; Nicolaas E P Deutz; Srinivasan Dasarathy
Journal:  Hepatology       Date:  2017-04-28       Impact factor: 17.425

2.  Diuretic treatment in high-risk acute decompensation of advanced chronic heart failure-bolus intermittent vs. continuous infusion of furosemide: a randomized controlled trial.

Authors:  Simone Frea; Stefano Pidello; Alessandra Volpe; Federico Giovanni Canavosio; Alessandro Galluzzo; Virginia Bovolo; Antonio Camarda; Pier Giorgio Golzio; Fabrizio D'Ascenzo; Serena Bergerone; Mauro Rinaldi; Fiorenzo Gaita
Journal:  Clin Res Cardiol       Date:  2019-06-29       Impact factor: 5.460

3.  The Efficacy of Lactulose for the Treatment of Hyperammonemic Encephalopathy Due to Severe Heart Failure.

Authors:  Koichi Narita; Eisuke Amiya; Nobutaka Kakuda; Hidehiro Kaneko; Masaru Hatano; Issei Komuro
Journal:  Diagnostics (Basel)       Date:  2020-01-27

4.  Prognostic Role of Ammonia in Critical Care Patients Without Known Hepatic Disease.

Authors:  Lina Zhao; Joseph Harold Walline; Yanxia Gao; Xin Lu; Shiyuan Yu; Zengzheng Ge; Huadong Zhu; Yi Li
Journal:  Front Med (Lausanne)       Date:  2020-10-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.